Back to Search
Start Over
Preventive drug therapy and contralateral breast cancer:summary of the evidence of clinical trials and observational studies
- Source :
- Bens, A, Langballe, R, Bernstein, J L, Cronin-Fenton, D, Friis, S & Mellemkjaer, L 2019, ' Preventive drug therapy and contralateral breast cancer : summary of the evidence of clinical trials and observational studies ', Acta Oncologica, vol. 58, no. 11, pp. 1581-1593 . https://doi.org/10.1080/0284186X.2019.1643915, Acta Oncol
- Publication Year :
- 2019
-
Abstract
- Background: Breast cancer patients have a lifelong 2–4-fold increased risk of developing a second primary tumor in the contralateral breast compared with the risk for a first primary breast cancer in the general female population. Prevention of contralateral breast cancer (CBC) has received increased attention during recent decades. Here, we summarize and discuss the available literature on drug preventive therapy and CBC. Results: The endocrine-targetting drugs, tamoxifen and aromatase inhibitors are used as standard adjuvant treatment for estrogen receptor (ER)-positive breast cancer. Both are associated with relative risk reductions of CBC of up to 50%, but incur serious side effects. Several prescription drugs originally developed for other purposes, including bisphosphonates, statins, non-steroidal anti-inflammatory drugs, metformin, anti-hypertensives and retinoids, have shown anti-cancer activity in preclinical models. However, results of observational studies on CBC are sparse and inconsistent, with only statins demonstrating promise as preventive agents and a potential treatment option for ER-negative breast cancer patients. Conclusion: Future studies are needed to assess the effect of statins in risk reduction and to identify other drugs with chemopreventive potential against CBC. Eventually, efforts must be directed towards identifying those breast cancer patients likely to benefit most from specific preventive therapies.
- Subjects :
- Oncology
Retinoids/therapeutic use
Antineoplastic Agents, Hormonal/therapeutic use
Estrogen receptor
030218 nuclear medicine & medical imaging
0302 clinical medicine
Breast Neoplasms/prevention & control
skin and connective tissue diseases
media_common
Randomized Controlled Trials as Topic
Diphosphonates
Aromatase Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Neoplasms, Second Primary
Hematology
General Medicine
Metformin
Observational Studies as Topic
030220 oncology & carcinogenesis
Female
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Diphosphonates/therapeutic use
medicine.drug
Drug
medicine.medical_specialty
Antineoplastic Agents, Hormonal
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
media_common.quotation_subject
Antineoplastic Agents
Breast Neoplasms
Article
03 medical and health sciences
Retinoids
Pharmacotherapy
Breast cancer
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Metformin/therapeutic use
Antihypertensive Agents
Antihypertensive Agents/therapeutic use
business.industry
Antineoplastic Agents/therapeutic use
medicine.disease
Neoplasms, Second Primary/prevention & control
Clinical trial
Tamoxifen
Tamoxifen/therapeutic use
Relative risk
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Aromatase Inhibitors/therapeutic use
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Bens, A, Langballe, R, Bernstein, J L, Cronin-Fenton, D, Friis, S & Mellemkjaer, L 2019, ' Preventive drug therapy and contralateral breast cancer : summary of the evidence of clinical trials and observational studies ', Acta Oncologica, vol. 58, no. 11, pp. 1581-1593 . https://doi.org/10.1080/0284186X.2019.1643915, Acta Oncol
- Accession number :
- edsair.doi.dedup.....97168409e4d819de2bd2985da833eb4b